Welcome to our dedicated page for MNK news (Ticker: MNK), a resource for investors and traders seeking the latest updates and insights on MNK stock.
The MNK news page on Stock Titan aggregates company-issued updates and media coverage related to Mallinckrodt plc and its subsequent branded therapeutics identity, Keenova Therapeutics. Recent press releases describe Mallinckrodt as a global specialty pharmaceutical company with a Brands business focused on autoimmune and rare diseases and a Par Health business that includes generic drugs, sterile injectables and active pharmaceutical ingredients.
News items for MNK include announcements on corporate transactions, such as the completion of the merger between Mallinckrodt and Endo, Inc., and the spin-off of the combined generics and sterile injectables businesses under the Par Health name. These releases also explain that, moving ahead, Mallinckrodt will be known as Keenova Therapeutics, a branded therapeutics company focused on helping patients with rare or unaddressed conditions.
Investors and followers of MNK can find updates on financial results, including quarterly net sales and segment performance for Specialty Brands, Generics and Sterile Injectables as reported by the company. Other news covers developments in key branded products, such as Acthar Gel and XIAFLEX, as well as communications about clinical and medical affairs activities, including data presentations related to TERLIVAZ for hepatorenal syndrome.
Additional coverage includes leadership and governance announcements, such as board appointments and executive changes, along with guidance and commentary on the company’s strategy around its Brands and Par Health businesses. For users tracking MNK, this news feed provides a central view of the company’s own disclosures on its therapeutic focus, portfolio evolution, corporate structure and branded transition to Keenova Therapeutics.
Keenova Therapeutics (NASDAQ:MNK) on May 4, 2026 launched a national consumer and disease awareness campaign, Don't Be a Viking, focused on Dupuytren's contracture.
The campaign features 30- and 15-second TV spots, streaming and digital placements, and directs people to FindaHandSpecialist.com to connect with hand specialists and learn about nonsurgical treatment options.
Keenova (NASDAQ:MNK) will present new clinical analysis of TERLIVAZ® (terlipressin) at Digestive Disease Week, May 2-5, 2026. The presentation reports preliminary real-world treatment patterns and outcomes for hepatorenal syndrome-acute kidney injury (HRS-AKI) from seven U.S. hospitals and aims to inform clinical practice.
Keenova Therapeutics (NASDAQ:MNK) will report its first quarter 2026 financial results on May 12, 2026 before market open and will host a conference call the same day.
The live call is scheduled for 8:00 a.m. ET, with an audio webcast accessible via the Investor Relations site and a replay available after the event.
Keenova (NYSE:MNK) reported robust Q4 2025 results with net sales from continuing operations of $543.0M, driven by Acthar Gel $205.6M (+48%) and XIAFLEX $156.5M. Adjusted EBITDA from continuing operations was $210M–$220M and loss from continuing operations was $(105.0M)–(115.0M).
The company provided 2026 guidance of $1.94B–$2.00B net sales and $730M–$760M Adjusted EBITDA, and expects ~ $100M pre-tax merger synergies in 2026 toward a $150M run-rate.
Keenova Therapeutics (NYSE:MNK) will present new clinical analysis of TERLIVAZ (terlipressin) at the Society of Hospital Medicine Converge, March 29–April 1, 2026.
The presentation reports real-world utilization patterns and outcomes in hospitalized U.S. adults with hepatorenal syndrome‑acute kidney injury (HRS‑AKI). According to the company, TERLIVAZ is the first and only FDA‑approved therapy to improve kidney function in adults with HRS‑AKI. The study is a retrospective cohort authored by A. Sidney Barritt IV and colleagues.
Keenova (MNK) announced first-time publication of a Phase 4 retrospective analysis of XIAFLEX® (collagenase clostridium histolyticum) for recurrent Dupuytren contracture after surgery.
The multicenter review covered patients treated between January 2010 and August 2020 across 10 U.S. clinical centers, measured joint contracture changes within 12 months, and found adverse events consistent with prior CCH reports.
Keenova (NASDAQ:MNK) presented previously unpublished Phase 2 extension data on collagenase clostridium histolyticum (CCH) for plantar fibromatosis at the ACFAS Annual Meeting Feb 24–27, 2026. Findings suggest a safety profile consistent with earlier Phase 2 results and support potential long‑term safety, efficacy, and durability.
Keenova is conducting a pivotal Phase 3 trial for CCH in plantar fibromatosis, with topline results expected mid‑2026.
Keenova (NASDAQ:MNK) announced a peer‑reviewed manuscript in Journal of Foot and Ankle Surgery reporting real‑world treatment patterns for plantar fibromatosis and highlighted persistent symptoms after conservative care. The company said it is actively evaluating collagenase clostridium histolyticum (CCH) in a Phase 3 trial currently underway (Feb 16, 2026).
The study notes no FDA‑approved nonsurgical options and calls for more research on long‑term outcomes and effective therapies.
Keenova (NASDAQ:MNK) announced it reached a milestone on Jan 21, 2026: 100,000 patients have been prescribed XIAFLEX to treat Peyronie's disease. XIAFLEX is described as the only FDA‑approved nonsurgical therapy for adult men with a palpable plaque and curvature >30 degrees at treatment start. Keenova plans expanded 2026 awareness campaigns, amplified patient voices on social media, and broader access to a mixed‑reality injection simulator for providers.
Keenova Therapeutics (NASDAQ:MNK) announced a Keenova‑sponsored presentation on Dupuytren's contracture (DC) at the American Association for Hand Surgery Annual Meeting, January 13–17, 2026. The presentation, led by Dr. Philip Blazar, reports results from a national patient survey on perceptions, attributes, and satisfaction with DC diagnosis and treatment options including surgery, collagenase clostridium histolyticum (CCH/XIAFLEX), and needle aponeurotomy.
The analysis highlights gaps in patient awareness and opportunities to improve education and patient–provider conversations to support earlier recognition and better treatment outcomes.